Pegylated interferon alpha‐2a showed no clear difference in sustained virological response 6 months after stopping treatment compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in treatment discontinuation compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in adverse events compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in death compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in relapse(recurrence after stopping) compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a may leads to higher end‐of‐treatment response compared with standard interferon (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Standard interferon plus ribavirin may leads to higher treatment discontinuation compared with standard interferon alone (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Pegylated interferon plus ribavirin may leads to lower relapse(recurrence after stopping) compared with pegylated interferon alone (low certainty).
Pegylated interferon plus ribavirin showed no clear difference in end‐of‐treatment response compared with pegylated interferon alone (low certainty).
Pegylated interferon plus ribavirin may leads to higher sustained virological response compared with pegylated interferon alone (low certainty).
Pegylated interferon plus ribavirin showed no clear difference in treatment discontinuation compared with pegylated interferon alone (low certainty).
Pegylated interferon plus ribavirin may leads to higher adverse events compared with pegylated interferon alone (low certainty).
Standard interferon showed no clear difference in death compared with placebo or control (low certainty).
Standard interferon showed no clear difference in relapse(recurrence after stopping intervention) compared with placebo or control (low certainty).